BriaCell Files Patent Application for Novel Immune Therapies for Multiple Disease Indications
20 May 2020 - 8:30PM
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, announces that it has filed a provisional patent
application with the U.S. Patent and Trademark Office (USPTO)
outlining a novel vaccine platform to selectively deliver antigens
of interest to immune cells to induce immune responses toward
pathogens including SARS-CoV-2 virus or cancer cells, or reduce
immune responses in the case of autoimmune or allergic diseases.
The patent application, entitled “MULTI-VALENT
IMMUNOSTIMULATORS FOR INFECTIOUS DISEASES, AUTOIMMUNE DISEASES,
ALLERGIC DISEASES AND CANCER”, describes a platform to generate
multi-valent reagents carrying an antigen (such as an antigen from
SARS-CoV-2) and delivering it to immune cells such as dendritic
cells, a type of antigen-presenting cell crucial for the induction
and modulation of immune responses. The expected effect is a
targeted therapy envisioned to selectively destroy infectious
agents or cancer cells with minimal negative effect on normal
cells. This may mean less severe side effects for the treated
patients compared to other therapies. The technology also has uses
for autoimmune diseases and allergic diseases. The Company cautions
that these novel therapeutics are still under early-stage research
and development and is not making any express or implied claims as
to their success in cancer treatment or commercial viability. The
patent application seeks protection for, among others, the design
of new therapeutics and methods for their use.
BriaCell has recently filed several
provisional patent applications related to (1) immunotherapy;
(2) antibody-based treatment; and (3) antigen-based induction of
immune response, including:
Patent Application 1 (April 14, 2020 press
release): Immunotherapy Approach
- “INDUCING IMMUNE RESPONSES BY TRANSFORMING CANCER CELLS INTO
ANTIGEN-PRESENTING CELLS”;
- Based on molecular analyses of BriaCell’s whole-cell
immunotherapy anti-tumor product candidate, designed to stimulate
the immune system to recognize and destroy the patient’s tumors by
acting as antigen-presenting cells.
Patent Application 2 (April 21, 2020 press
release): Antibody-Based Treatment Approach
- “COMPUTER-GUIDED DESIGN OF ANTIBODIES INCLUDING NEUTRALIZING
SARS-CoV-2 BINDING AGENTS”;
- Antibodies designed and selected to neutralize SARS-CoV-2 using
computer simulation – envisioned to prevent and treat the
life-threatening symptoms of COVID-19;
- BriaCell hypothesizes that antibodies may quickly and
specifically recognize the SARS-CoV-2 virus, bind to it, and
neutralize it.
Patent Application 3 (May 20, 2020 press
release): Antigen-Based Immune Response Approach
- “MULTI-VALENT IMMUNOSTIMULATORS FOR INFECTIOUS DISEASES,
AUTOIMMUNE DISEASES, ALLERGIC DISEASES AND CANCER”;
- Platform to generate multi-valent reagents carrying an antigen
(such as an antigen from SARS-CoV-2) and delivering it to immune
cells to induce (or dampen) immune responses;
- Anticipated effect is a targeted therapy envisioned to
selectively destroy infectious agents or cancer cells with minimal
negative effect on normal cells.
The Company cautions that COVID-19 therapeutic
development is still under early-stage research and development and
is not making any express or implied claims that it has the ability
to treat, prevent or eliminate the COVID-19 virus at this time.
The Company’s scientific experts have read and
approved the scientific disclosures contained in the press
release.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics
Corp.:William V. Williams, MDPresident & CEOPhone:
1-888-485-6340
BriaCell Therapeutics
Corp.:Farrah DeanManager, Corporate DevelopmentEmail:
farrah@BriaCell.com Phone: 1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024